SCHEMBL4886749

SCHEMBL4886749

Cc1ccc(C(=O)O)cc1-n1cnc2ccc(Br)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.52
MCL1 Q07820 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1140575 0.88 MAPK14 (0.52) MAPK14MCL1
SCHEMBL3100316 0.87 MAPK14 (0.53) MAPK14
SCHEMBL3339036 0.84 HPGD (0.53) MAPK14
SCHEMBL4884233 0.82 HCAR1 (0.45) MAPK14MCL1
SCHEMBL3110439 0.81 MAPK14 (0.48) MAPK14
SCHEMBL3110427 0.81 MAPK14 (0.48) MAPK14
SCHEMBL3118832 0.81 MAPK14 (0.51) MAPK14
SCHEMBL3110329 0.80 MAPK14 (0.49) MAPK14
SCHEMBL1139995 0.80 MAPK14 (0.81) MAPK14
SCHEMBL3339241 0.78 MAPK14 (0.46) MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275022-A1 Substituted Quinazolones as Anti-Cancer Agents ASTRAZENECA AB (SE) 2008-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275022-A1 Substituted Quinazolones as Anti-Cancer Agents BRAF, NRAS, RAF1 MAPK14 153/4885MCL1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.